Search for Clinical Trial Results

Sponsored By

Glomerulonephritis, Membranoproliferative - 10 Studies Found

Status Study
Completed Study Name: Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
Condition: Glomerulonephritis, Membranoproliferative
Date: 2006-01-10
Interventions: Drug: Rituximab The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses
Active, not recruiting Study Name: Eculizumab in Primary MPGN
Condition: Membranoproliferative Glomerulonephritis
Date: 2014-03-17
Interventions: Drug: Eculizumab Other Name: Soliris
Not yet recruiting Study Name: Daratumumab in Treatment of PGNIMD and C3 GN
Condition: Membranoproliferative Glomerulonephritis
Date: 2017-03-20
Interventions: Drug: Daratumumab Open-label Other Name: Darzalex
Completed Study Name: BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis
Condition:
  • Glomerulonephritis, Membranoproliferative
  • Lupus Nephritis

    • Date: 1999-11-03
    Interventions: Drug: BG9588
Not yet recruiting Study Name: A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN
Condition:
  • C3 Glomerulonephritis
  • Dense Deposit Disease
  • Dense Deposit Disease
  • Membranoproliferative Glomerulonephritis<
    Date: 2010-10-13
    Interventions: Drug: Eculizumab 900 mg IV once a week x 4 weeks, 1200 mg
Terminated Study Name: Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
Condition:
  • Dense Deposit Disease
  • Membranoproliferative Glomerulonephritis
    Date: 2013-01-29
    Interventions: Drug: CDX-1135 Other Names:
    • TP10
    • sCR1
Withdrawn Study Name: TP10 Use in Patients With C3 Glomerulopathy (C3G)
Condition: Dense Deposit Disease
Date: 2014-11-05
Interventions: Drug: TP10 All patients will be enrolled through the University of Iowa. This study will follow a patien
Withdrawn Study Name: Sulodexide Treatment in Patients With Dense Deposit Disease
Condition: Dense Deposit Disease
Date: 2007-12-20
Interventions: Drug: Sulodexide 200 mg per day in an oral gelcap form
Recruiting Study Name: Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
Condition:
  • IgAN
  • Lupus Nephritis
  • MN

  • Date: 2016-02-10
    Interventions:
    • Biological: OMS721 Biological: